Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK To Co-Promote Advair With Mitsubishi Tanabe Pharma In Japan

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline and Mitsubishi Tanabe Pharma will be co-promoting chronic obstructive pulmonary disease treating Advair Diskus (fluticasone propionate plus salmeterol) staring April. Through the collaboration, GSK aims to increase awareness and provide Japanese patients information on the drug as a treatment option. In Japan, there are 4.5 million COPD patients and 2,500 people die of the disease annually. (Click here for more - Japanese language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel